IL‐33 is known to drive Th‐2 responses and play a crucial role in allergy and lung‐related inflammatory conditions.44 Our novel findings in relation to IL‐31 and IL‐33 warrant further investigation in a larger cohort of alloHSCT recipients as these may serve as biomarkers that can be used for risk prediction of Aspergillus infections post‐alloHSCT. The gene discussed is IL31; the disease is Allergy.